ScripRussia’s attack on Ukraine has become a cause of concern for pharmaceutical companies across the world as parts of the well-oiled machinery that drives drug production, from clinical trials to logisti
In VivoBusiness development activity lies at the heart of AstraZeneca PLC ’s hopes to return to growth in 2017 after the loss this year of patent protection for its mega-blockbuster statin Crestor (rosu
ScripAstraZeneca PLC 's externalization strategy in the future will probably engage more in partnering collaborations with other drug makers that generate recurring revenue and focus less on the sell-off
In VivoFinancings During the first quarter of 2016, biopharma financing totaled $5.7 billion, a 56% decrease over the previous quarter's $13.1 billion. (Keep in mind, over half of the Q4 2015 total came from